Editas Medicine (EDIT) Total Liabilities (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Total Liabilities of $159.2 million for Q4 2025, down 23.19% year-over-year from $207.3 million in Q4 2024, and down 15.43% quarter-over-quarter from $188.3 million in Q3 2025.
Editas Medicine (EDIT) Total Liabilities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Total Liabilities for 11 consecutive years, with $159.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 23.19% year-over-year to $159.2 million; the TTM figure through Dec 2025 stood at $159.2 million (down 23.19% YoY), while the FY2025 annual figure was $159.2 million, down 23.19% from the prior year.
- Total Liabilities retreated to $159.2 million in Q4 2025 per EDIT's latest filing, from $188.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $207.3 million in Q4 2024 and bottomed at $110.3 million in Q1 2022.
- Historically, Total Liabilities has averaged $150.8 million across 5 years, with a median of $146.3 million in 2023.
- Annual changes were most pronounced in 2021 — Total Liabilities tumbled 38.71% — and 2024, when it jumped 38.16%.
- Editas Medicine's Total Liabilities stood at $123.8 million in 2021, then gained by 24.06% to $153.6 million in 2022, then decreased by 2.33% to $150.1 million in 2023, then surged by 38.16% to $207.3 million in 2024, then slipped by 23.19% to $159.2 million in 2025.
- Business Quant data shows EDIT's Total Liabilities at $159.2 million in Q4 2025, $188.3 million in Q3 2025, and $191.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 159.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 159.25 Mn |
| Sep 30, 2025 | 188.30 Mn |
| Jun 30, 2025 | 191.39 Mn |
| Mar 31, 2025 | 201.23 Mn |
| Dec 31, 2024 | 207.32 Mn |
| Sep 30, 2024 | 151.93 Mn |
| Jun 30, 2024 | 152.79 Mn |
| Mar 31, 2024 | 145.95 Mn |
| Dec 31, 2023 | 150.06 Mn |
| Sep 30, 2023 | 144.19 Mn |
| Jun 30, 2023 | 142.04 Mn |
| Mar 31, 2023 | 146.63 Mn |
| Dec 31, 2022 | 153.64 Mn |
| Sep 30, 2022 | 116.28 Mn |
| Jun 30, 2022 | 115.42 Mn |
| Mar 31, 2022 | 110.35 Mn |
| Dec 31, 2021 | 123.84 Mn |
| Sep 30, 2021 | 130.23 Mn |
| Jun 30, 2021 | 142.52 Mn |
| Mar 31, 2021 | 142.30 Mn |